|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-10-8
|
|
pubmed:abstractText |
Public insurance plans for pharmaceuticals in Canada differ substantially across provinces in the conditions under which pharmaceuticals are reimbursed. Coxibs provide a good example. Québec had no restrictions on reimbursement for these drugs. Ontario required physicians to submit the clinical indications for their use on the prescription. British Columbia required physicians to seek and receive prior authorisation from the drug plan.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
H
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0168-8510
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
84
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1-13
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:17570558-Analgesics,
pubmed-meshheading:17570558-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:17570558-Canada,
pubmed-meshheading:17570558-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:17570558-Evidence-Based Medicine,
pubmed-meshheading:17570558-Formularies as Topic,
pubmed-meshheading:17570558-Humans,
pubmed-meshheading:17570558-National Health Programs,
pubmed-meshheading:17570558-Organizational Policy,
pubmed-meshheading:17570558-Reimbursement Mechanisms,
pubmed-meshheading:17570558-Retrospective Studies
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
|
|
pubmed:affiliation |
Centre for Evaluation of Medicines, 105 Main Street East, Level P1, Hamilton, ON L8N 1G6, Canada. marshd@mcmaster.ca
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
